With the approval of aspart, Biocon says it will become the first company to receive approvals for two interchangeable insulin drugs in the US, helping it make a strong entry into that market. This also proves that the company has the science and vertical integration required to get to the US market, it said.from Industry-Economic Times
Read The Rest:economictimes...
